Scientists hunt for clues to stop corneal graft rejection
NCT ID NCT05009407
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether a protein called CD160 appears in new blood and lymph vessels that grow in the cornea after a transplant. Researchers analyzed tissue from 43 patients who had corneal transplant surgery. The goal was to see if CD160 is linked to graft rejection, which could lead to better treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If CD160 is found in corneal vessels, it could point toward new ways to prevent graft rejection.
- What could go wrong
- This is a small, completed observational study analyzing tissue samples. It does not test any treatment, so any future applications are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOGENESIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Damien JOLLY
Reims, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.